Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy in Pre-treated RAS/BRAF Wild Type Metastatic Colorectal Cancer Patients.

NCT05291156 is registered in ClinicalTrials.gov with University of Campania Luigi Vanvitelli as lead sponsor.

NCT NCT05291156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05291156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy in Pre-treated RAS/BRAF Wild Type Metastatic Colorectal Cancer Patients.
Lead sponsor
University of Campania Luigi Vanvitelli
Phase
Phase 2
Overall status
Unknown status
Start date
July 21, 2022
Completion date
July 1, 2025
Enrollment
173 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer